Are microcalcifications of the breast something to be worry about?

 

Ask a Question

Q: What does it mean to have microcalcifications of the breast? I have had a mammogram and need to return due to microcalcifications. Are these something I need to be worried about? I have a huge history of breast cancer in my family, including my mom and sister both passing of breast cancer.

A: Microcalcifications are tiny specks of the mineral calcium—as small as a grain of salt—that are sometimes seen in breast tissue when viewed on a mammogram (screening breast x-ray). These mineral specks may be individual or they may form clusters.

Most microcalcifications are noncancerous cells. In some cases, they may be indicators of a highly curable, early-stage breast cancer known as ductal carcinoma in situ (DCIS). If a mammogram determines that some microcalcifications may be questionable, a biopsy will determine if they are normal or not.

--Bernice Crook, RN, OCN

Many cancers can be identified early, when they are most treatable, through sophisticated screening tests.

Latest Cancer News
Avastin® Linked with Increased Risk of Blood Clots

November 20, 2008 — According to a combined analysis of previously published studies, cancer patients who use Avastin® (bevacizumab) may have an increased risk of venous thromboembolism (a blood clot in a vein). These results were published in the Journal of the American Medical Association.

Addition of Avastin® to Paraplatin®, Taxol®, and Erbitux® Promising for Advanced NSCLC

November 20, 2008 — Researchers affiliated with the Southwest Oncology Group have reported that the four-drug combination of chemotherapy agents Paraplatin® (carboplatin) and Taxol® (paclitaxel) plus targeted therapies Avastin® (bevacizumab) and Erbitux® (cetuximab) is safe and may improve survival in patients with advanced non–small cell lung cancer (NSCLC). The details of this study were presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology November 13-15.

Avastin® Increases Risk of Venous Thromboembolism

November 20, 2008 — Researchers from Stony Brook University have reported that the use of Avastin® (bevacizumab) increases the risk of thromboembolism. The details of this review were published in the November 19, 2008 issue of the Journal of the American Medical Association.

Select news items provided by Reuters Health